Ranibizumab
- TRADE NAME: Lucentis (Genentech)
- INDICATIONS: Neovascular (wet) age-related macular degeneration, macular edema (following retinal vein occlusion)
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Monoclonal antibody, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 9 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
Contra-indicated in patients with ocular or periocular infections.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ranibizumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/13/2024
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
